Drug eases GVHD symptoms in patients who had stem cell transplant

12/1/2011 | U.S. News & World Report

Daily, low-dose injections of interleukin-2 eased symptoms of graft-versus-host disease, or GVHD, in cancer patients who underwent allogeneic hematopoietic stem cell transplantation, according to a study published in the New England Journal of Medicine. Of 23 patients given the drug for eight weeks, 12 showed improvement, according to the study.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC